Literature DB >> 21325449

Epidermal growth factor receptor as a biomarker for cervical cancer.

T Soonthornthum1, H Arias-Pulido, N Joste, L Lomo, C Muller, T Rutledge, C Verschraegen.   

Abstract

This review focuses on the different modes of expression of the epidermal growth factor receptor (EGFR). All methods used to assess EGFR expression are critically analyzed and insights into the use of inhibitors of EGFR for treatment of cervical cancer are discussed. Currently, expression of EGFR as a biomarker for prognosis or for treatment of cervical cancer is not defined for clinical use.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21325449     DOI： 10.1093/annonc/mdq723

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


  39 in total

1.  FTS is responsible for radiation-induced nuclear phosphorylation of EGFR and repair of DNA damage in cervical cancer cells.

Authors:  Sridhar Muthusami; D S Prabakaran; Jae-Ran Yu; Woo-Yoon Park
Journal:  J Cancer Res Clin Oncol       Date:  2014-08-24       Impact factor: 4.553

2.  E5 can be expressed in anal cancer and leads to epidermal growth factor receptor-induced invasion in a human papillomavirus 16-transformed anal epithelial cell line.

Authors:  Erin Isaacson Wechsler; Sharof Tugizov; Rossana Herrera; Maria Da Costa; Joel M Palefsky
Journal:  J Gen Virol       Date:  2018-04-06       Impact factor: 3.891

3.  The inhibitory effect of a new scFv/tP protein as siRNA delivery system to target hWAPL in cervical carcinoma.

Authors:  Huilin Zhang; Yuan Mao; Feng Zhang; Chunping Ye; Hua Tong; Yiping Su; Jin Zhu
Journal:  Mol Cell Biochem       Date:  2014-02-25       Impact factor: 3.396

Review 4.  Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers.

Authors:  Henry D Reyes; Kristina W Thiel; Matthew J Carlson; Xiangbing Meng; Shujie Yang; Jean-Marie Stephan; Kimberly K Leslie
Journal:  Mol Diagn Ther       Date:  2014-04       Impact factor: 4.074

5.  Rational creation and systematic analysis of cervical cancer kinase-inhibitor binding profile.

Authors:  Min Han; Dongdong Sun
Journal:  J Comput Aided Mol Des       Date:  2019-06-15       Impact factor: 3.686

6.  Elevated expression of G protein-coupled receptor 30 (GPR30) is associated with poor prognosis in patients with uterine cervical adenocarcinoma.

Authors:  Yoshihiko Ino; Taishi Akimoto; Akira Takasawa; Kumi Takasawa; Tomoyuki Aoyama; Asako Ueda; Misaki Ota; Kazufumi Magara; Yohei Tagami; Masaki Murata; Tadashi Hasegawa; Tsuyoshi Saito; Norimasa Sawada; Makoto Osanai
Journal:  Histol Histopathol       Date:  2019-09-04       Impact factor: 2.303

7.  Association between ErbB3 genetic polymorphisms and coronary artery disease in the Han and Uyghur populations of China.

Authors:  Buamina Maitusong; Xiang Xie; Yi-Tong Ma; Zhen-Yan Fu; Yi-Ning Yang; Xiao-Mei Li; Fen Liu; Bang-Dang Chen; Min-Tao Gai
Journal:  Int J Clin Exp Med       Date:  2015-09-15

8.  EGFR protein expression and gene amplification in squamous intraepithelial lesions and squamous cell carcinomas of the cervix.

Authors:  Qing Li; Yongfeng Tang; Xue Cheng; Jie Ji; Jingmin Zhang; Xiaojun Zhou
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

9.  Candidate biomarkers for cervical cancer treatment: Potential for clinical practice (Review).

Authors:  Miho Iida; Kouji Banno; Megumi Yanokura; Kanako Nakamura; Masataka Adachi; Yuya Nogami; Kiyoko Umene; Kenta Masuda; Iori Kisu; Takashi Iwata; Kyoko Tanaka; Daisuke Aoki
Journal:  Mol Clin Oncol       Date:  2014-06-23

10.  Genetic variations in EGFR and ERBB4 increase susceptibility to cervical cancer.

Authors:  Duanduan Ma; Raymond L Hovey; Zhengyan Zhang; Samantha Fye; Phyllis C Huettner; Ingrid B Borecki; Janet S Rader
Journal:  Gynecol Oncol       Date:  2013-08-06       Impact factor: 5.482
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.